Atlas Trials

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Clinical trial NCT05331183 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05331183
Sponsor
Vertex Pharmaceuticals Incorporated
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2022-11-23
Primary completion
2027-04-06
Enrollment
297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.